Related references
Note: Only part of the references are listed.Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
Alexander Kutikov et al.
BJU INTERNATIONAL (2010)
UK guidelines for the systemic treatment of renal cell carcinoma
Paul Nathan et al.
BRITISH JOURNAL OF HOSPITAL MEDICINE (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Surgical Resection of Renal Cell Carcinoma After Targeted Therapy
Anil A. Thomas et al.
JOURNAL OF UROLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
Brian Shuch et al.
BJU INTERNATIONAL (2008)
Sunitinib for treatment of advanced renal cell cancer: Primary tumor response
Astrid A. M. Van der Veldt et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Vitaly Margulis et al.
JOURNAL OF UROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
Share Paper
